[{"orgOrder":0,"company":"Asceneuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ASN90","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Asceneuron \/ Not Applicable"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ASN90","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Asceneuron \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Ferrer Internacional"}]

Find Clinical Drug Pipeline Developments & Deals for ASN90

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.

                          Brand Name : ASN90

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 22, 2023

                          Lead Product(s) : ASN90

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Ferrer Internacional

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Findings published demonstrated increased survival in preclinical model of Alzheimer's disease after administration of clinical molecule ASN90, an O–GlcNAcase inhibitor, as well as significant motor impairment and astrogliosis effect in a Parkinson's m...

                          Brand Name : ASN90

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 01, 2022

                          Lead Product(s) : ASN90

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank